CureVac Shareholders Face Final Deadline in BioNTech Takeover
Published on 11/28/2025 at 17:48 | Redaktion boerse-global.de
Time is running out for investors in CureVac as the company’s independence draws to a close. The German biopharmaceutical firm, once celebrated as a promising contender in the global vaccine race, is now being fully integrated into its Mainz-based competitor BioNTech. Shareholders have only days remaining to participate in the acquisition before the company’s stock is delisted from public markets.
The transaction is structured as a pure share exchange, with CureVac stockholders receiving 0.05363 BioNTech shares for each of their current holdings. Market participants should note two crucial dates in this process:
- Tuesday, December 2, 2025 (6:00 PM Eastern Time): The operational cutoff for tendering shares
- Wednesday, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
